YLYu-Feng Li

Yu-Feng Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yu-Feng Li has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Cheng-Hua Yu

    Zunhua People's Hospital, Zunhua, China

    1 shared publication
  • De-Yan Li

    Zunhua People's Hospital, Zunhua, China

    1 shared publication
  • Guo-Hong Zheng

    Department of Chemoradiotherapy, Tangshan People’s Hospital, No. 65, Shengli Road, Lunan District, Tangshan, 063000, Hebei Province, China

    1 shared publication
  • Jiang-Sheng Mi

    Zunhua People's Hospital, Zunhua, China

    1 shared publication
  • Jing-Jing Liu

    Department of Chemoradiotherapy, Tangshan People’s Hospital, No. 65, Shengli Road, Lunan District, Tangshan, 063000, Hebei Province, China

    1 shared publication
  • Jinghua Zhang

    North China University of Science and Technology; North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Hospital; Hebei Key Laboratory of Molecular Oncology

    1 shared publication

Latest Publications

  • Fatal Cytokine-Release Syndrome in A Patient Receiving Toripalimab: A Case Report

    by Yang Zhou, Guo-Hong Zheng, Na Li, Jing-Jing Liu, Xiao-Hong Wang, Yu-Feng Li

    Immune checkpoint inhibitors, a type of immunotherapy, have demonstrated optimal treatment efficacy in inducing durable antitumor responses in various cancers. Cytokine-release syndrome is a rare i... Plain language summary Immune checkpoint inhibitors (ICIs) have shown revolutionary efficacy in the treatment of multiple cancers. Cytokine-release syndrome (CRS) is a common and lethally adverse e...


  • WSTF acetylation by MOF promotes WSTF activities and oncogenic functions

    by Yuan-Yue Zhang, Shu-Qing Wang, Min Li, Yue-Hong Long, Yu-Feng Li, Yan-Kun Liu, Yu-Hui Li, Ya-Qi Wang, Jiang-Sheng Mi, Cheng-Hua Yu, et al.

    Williams syndrome transcription factor (WSTF) is a transcription factor and tyrosine kinase. WSTF overexpression promotes migration and proliferation of various cancers, and Ser158 (WSTFS158) phosphorylation plays an important role in this process. However, the role of the other posttranslational modifications of WSTF is unknown. Here, we report that lysine (K) 426 on WSTF is acetylated by MOF and deacetylated by SIRT1. Mechanistically, male-specific lethal (MSL) 1v1 interaction with WSTF facilitates its interaction with MOF for WSTF acetylation, which in turn promotes WSTFS158 phosphorylation. The kinase and transcriptional regulatory activity of WSTF were enhanced by acetylation. WSTFK426ac levels positively and significantly correlated with tumor size, histological grade, and age. Moreover, we demonstrated that acetylated WSTF promotes cancer cell proliferation, migration, invasion, and tumor formation. In conclusion, we identified the enzymes regulating WSTF K426 acetylation, and demonstrated an acetylation-dependent mechanism that modulates the activities of WSTF and contributes to tumorigenesis. Our findings provide new clues to study WSTF-mediated normal development and disease.